+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
R

Actively Recruiting

Researchers are evaluating pumitamig BNT327 combined with chemotherapy etoposidecarboplatin compared to atezolizumab combined with the same chemotherapy for participants with previously untreated extensive-stage small-cell lung cancer. This Phase III, multisite, randomized, double-blinded study aims to compare these treatments to better understand options for first-line ES-SCLC therapy. The study has two stages involving different treatment arms. Stage 1 includes two pumitamig doses combined with chemotherapy and one control arm with atezolizumab plus chemotherapy. Stage 2 has one pumitamig dose treatment arm and a control arm with atezolizumab plus chemotherapy. Participants receive intravenous infusions of study drugs, with the option to switch from carboplatin to cisplatin if needed. Each stage has a screening period up to 21 days, followed by induction and maintenance treatment until disease progression, intolerable side effects, withdrawal, study end, or up to 2 years, then a safety and survival follow-up period. Participants undergo screening to confirm eligibility, then receive treatments according to randomization. Assessments include survival, progression-free survival, response rates, duration of response, and quality of life measured through questionnaires. Safety monitoring tracks adverse events and treatment delays or discontinuations. Follow-up includes safety visits and survival tracking, with total participation lasting up to approximately 46 months from start. The study is designed to monitor long-term outcomes and tolerability of these combinations in ES-SCLC treatment.

Age: 18Years +All GendersPhase 3
225 locations